Results 151 to 160 of about 46,241 (267)

Bridging computational and clinical strategies for presurgical identification of epileptogenic networks

Epilepsia Open, Volume 11, Issue 5, Page 1525-1540, October 2026.
Abstract Objective About one third of epilepsy patients are drug‐resistant. Resective epilepsy surgery remains a key treatment option but depends critically on accurate identification of the seizure onset zone (SOZ), which is still guided mainly by subjective visual inspection of electrophysiological signals.
Tena Dubcek, Debora Ledergerber, Kristina Koenig, Adham Elshahabi, Rafael Polania, Lukas Imbach   +5 more
wiley   +1 more source

Guidelines for Seizure Prophylaxis in Patients with Aneurysmal Subarachnoid Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society. [PDF]

Neurocrit Care
Rowe AS, Zafar SF, Tesoro E, Gilmore EJ, Johnson EL, Olson D, Rayi A, Ullman J, Yuan Y, Frontera JA.   +9 more
europepmc   +1 more source

Response to anti‐seizure medications in children carrying novel or previously reported HCN1 gene variants

Epilepsia Open, Volume 11, Issue 5, Page 1581-1589, October 2026.
Abstract Objective Variants in the HCN1 gene cause a syndrome of childhood epilepsy and developmental disability with a broad phenotypic range. Many affected children manifest with early infantile epileptic encephalopathy (EIEE) and highly drug‐resistant epilepsy.
Marium N. Khan, Nicholas P. Poolos
wiley   +1 more source

Functional and pharmacological characterization of the <i>SCN2A</i> variant p.C258R with mixed gain and loss of function causing developmental and epileptic encephalopathy type 11. [PDF]

Epilepsy Behav Rep
Köppel A, de Vries H, Jamili M, Stanke C, Brandl U, Leipold E, Heinemann SH.   +6 more
europepmc   +1 more source

DECREASE study: A European pool‐analysis of patients with significant reductions in concomitant antiseizure medications in cenobamate Early Access Programs

Epilepsia Open, Volume 11, Issue 5, Page 1812-1824, October 2026.
Abstract Objective To evaluate the effectiveness and tolerability of cenobamate in patients with a significant reduction in concomitant antiseizure medication (ASM) in European cenobamate Early Access Programs (EAPs). Method Anonymized patient data from real‐world studies/registries associated with European cenobamate EAPs were pooled.
Vicente Villanueva, Simona Lattanzi, Javier Peña‐Ceballos, Rhys H. Thomas, Juan Rodríguez‐Uranga, Zsófia Jordán, Bernhard J. Steinhoff, Randi von Wrede, Norman Delanty, Patrick B. Moloney, Roberta Roberti, Giovanni Boero, Laura Canafoglia, Nicola Specchio, Antonio Gambardella, Edoardo Ferlazzo, Francesca Felicia Operto, Elena Tartara, Hester Garratt, Dániel Fabó, Asier Gómez‐Ibáñez, Gustavo Torres‐Gaona, Yulia Novitskaya, Rainer Surges, Kevin Hampel, Andreas Schulze‐Bonhage   +25 more
wiley   +1 more source

Assessment of Potential Drug‐Drug Interactions in Hospitalized Patients With Cardiovascular Diseases at Kenyatta National Hospital, Nairobi, Kenya: A Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background and Aim Drug–drug interactions (DDIs) occur when the pharmacological effect of one medication is altered by the concurrent administration of another, potentially leading to reduced therapeutic efficacy or increased risk of adverse effects.
Brenda Koech, Ermias Terefe
wiley   +1 more source

Interaction of azapropazone with phenytoin.

, 2016
We recently observed a patient in whom we suspected an interaction of azapropazone with phenytoin resulting in phenytoin toxicity. This and a report of a similar case led us to investigate the effect of azapropazone on steady-state plasma phenytoin ...

core  

Physiologically Based Pharmacokinetic Modeling to Characterize the Disposition of Topiramate in Children with and without Obesity

The Journal of Clinical Pharmacology, Volume 66, Issue 10, October 2026.
Abstract Topiramate (TPM) is used to treat seizures in adults and children ≥2 years. In children, TPM dosing is body weight based. It is unknown whether children with obesity may benefit from an alternative dosing strategy. We developed a novel physiologically based pharmacokinetic (PBPK) model for TPM that accounts for age‐ and obesity‐related changes
Patricia D. Maglalang, Daniel Gonzalez, William J. Muller, Chi D. Hornik, Stuart L. Goldstein, Mobeen Rathore, Jennifer L. Ford, Stephen J. Balevic, Jaydeep Sinha, Andrea Edginton, Rachel G. Greenberg, Daniel K. Benjamin, Jia‐Yuh Chen, Kanecia O. Zimmerman, the Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee   +14 more
wiley   +1 more source

Investigation of the Prevalence of the <i>HLA-B*15:02</i> Allele in the Asian Populations: A Comprehensive Analysis Through Using AFND. [PDF]

Health Sci Rep
Biswas M, Murad MA, Ershadian M, Sukasem C.   +3 more
europepmc   +1 more source

Hyperhomocysteinemia and Vitamin B Deficiency as Potential Aggravating Factors in Huntington's Disease: A Prospective Monocentric Study

Movement Disorders, Volume 41, Issue 10, Page 2712-2722, October 2026.
Abstract Background Although not confirmed, some studies have suggested that elevated homocysteine levels are common in patients with Huntington's disease (HD). Its clinical relevance remains unclear. Objectives We aimed to assess vitamin B and homocysteine levels in HD patients and explore the relationships among hyperhomocysteinemia, vitamin B ...
Salomé Puisieux, Elise Pourié, Céline Bonnet, Lucie Hopes, Solène Frismand, Myriam Bronner, Virginie Roth, Marion Wandzel, Natacha Sloboda, Laetitia Lambert, Abderrahim Oussalah, Amélia Julien, Irina Rotaru, Rosa‐Maria Guéant‐Rodriguez, Jean Louis Guéant, Carine Bossenmeyer‐Pourié, Mathilde Renaud   +16 more
wiley   +1 more source